* Oscar Health Inc OSCR.N OSCR.K is expected to show a
rise in
quarterly revenue when it reports results on February 9.
* The New York City-based company is expected to report a
118.7% increase in revenue to $1.085 billion from $496.07
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Oscar Health Inc is
for a
loss of $1.16 per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Oscar
Health Inc
is $4, above its last closing price of $3.85.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.72 -0.73 -0.91 Missed -24.6
Jun. 30 2022 -0.51 -0.48 -0.53 Missed -10.8
Mar. 31 2022 -0.21 -0.21 -0.36 Missed -68.6
Dec. 31 2021 -0.85 -0.96 -0.95 Beat 1.5
Sep. -0.66 -0.66 -1.02 Missed -54.7
30 2021
Jun. 30 2021 -0.46 -0.46 -0.35 Beat 24.7
Mar. 31 2021 -0.53 -0.53 -0.98 Missed -83.7
This summary was machine generated February 8 at 02:28 GMT. All
figures in US dollars unless otherwise stated